Current Status of Biomaterials: Use and Development

  • Paul Didisheim
Part of the NATO ASI Series book series (NSSA, volume 235)


The rationale for including a talk on biomaterials in a conference on cardiovascular engineering is that engineers and materials scientists have over the years designed devices to replace various organs or perform certain functions in the body, and that the properties of the biomaterials as well as the design of the device influence the events that occur when such devices come into contact with blood and tissues.


Vascular Graft Small Business Innovation Research Total Artificial Heart Artificial Kidney Biomaterial Area 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moss AJ, Hamburger S, Moore RM, Jeng LL, Howie LI: Use of selected medical device implants in the United States, Advance Data, 191, 1988.Google Scholar
  2. 2.
    Didisheim P, Watson JT: Application of materials in medicine and dentistry: cardiovascular, In: Biomaterials Science: An Introductory Text (Eds., Ratner BD, Hoffman AS, Lemons JE, Schoen FJ), Academic Press, 1992, in press.Google Scholar
  3. 3.
    Biologic Testing of Medical Devices - Part 4. Selection of tests for interactions with blood. International Standard ISO10993–4, 1992, in press.Google Scholar
  4. 4.
    Williams DF: Consensus and definitions in biomaterials, In: Implant Materials in Biofunction, (Eds., DePutter C, deLange GL, DeGroot K, Lee AJC), Advances in Biomaterials, 8:11–71, Elsevier, Amsterdam, 1988.Google Scholar
  5. 5.
    Herring MB: The CF.e of endothelial seeding of prosthetic arterial bypass grafts, Surg. Ann., 23 (2): 157–171. 1991.Google Scholar
  6. 6.
    Hubbell JA, Massia SP: ylothelial cell-selective materials for tissue engineering in the vascular graft via a new receptor, Bio/Technology, 9: 568–572, 1991.PubMedCrossRefGoogle Scholar
  7. 7.
    Greisler HP, Endean ED, Klosak JJ, Ellinger J, Dennis JW, Butte K, Kim DU: Polyglactin 910/polydioxanone bicomponent totally resorbable vascular prostheses, J. Vasc. Surg., 7: 697–705, 1988.PubMedGoogle Scholar
  8. 8.
    Long MN, King VJ, Prasad KU, Freeman BA, Urry DW: Elastin repeat peptides as chemoattractants for bovine aortic endothelial cells, J. Cell. Physiol., 140: 512–518, 1988.CrossRefGoogle Scholar
  9. 9.
    Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF: Seeding of intravascular stents with genetically engineered endothelial cells, Circulation, 80: 1347–1353, 1989.PubMedCrossRefGoogle Scholar
  10. 10.
    Thompson JA, Haudenschild CC, Anderson KD, DiPietro JM, Anderson WF, Maciag C: Heparin-binding growth factor 1 induces the formation of organoid neovascular structures in-vivo, Proc. Natl. Acad. Sci. USA, 86: 7928–7932, 1989.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Paul Didisheim
    • 1
  1. 1.Biomaterials Program Devices and Technology Branch Division of Heart and Vascular Diseases National Heart, Lung, and Blood InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations